Small molecule inhibitors against EZH2, a key effector of the BRN2 signaling, restored differentiation and impaired invasion of melanoma cells in vitro (72, 113), and inhibited melanoma growth and metastasis in mouse models (135). This evidence concerns the gene POU3F2 and melanoma.